Participants will receive single oral dose of moxifloxacin in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.

Participants will receive single oral low dose of M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.

Participants will receive single oral high dose of M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment.Therefore, an AE can be any unfavorable and unintended sign (including an abnormallaboratory finding), symptom, or disease temporally associated with the use of amedicinal product, regardless if it is considered related to the medicinal product.Serious AE: AE that resulted in any of the following outcomes: death; life threatening;persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization;congenital anomaly/birth defect. TEAEs are defined as AEs that were reported orworsened on or after start of study drug dosing through the Safety Follow-up Visit.TEAEs included both serious TEAEs and non-serious TEAEs. Treatment related AEs:reasonably related to the study drug/study treatment.

Severity of adverse events (AE) were assessed by the investigator. The Investigator assessed the intensity of each AE and SAE reported during the study and assigned it to 1 of the following categories:

1. Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. 2. Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 3. Severe: A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Number of participants with severe adverse events were reported.

The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities from baseline were reported. Clinically Significance was decided by investigator.

Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.

The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities were reported. Clinically significance was decided by investigator.

AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.

Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.

Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.

The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.

Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

The effect of evobrutinib on baseline-corrected measurements of Heart rate was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The effect of evobrutinib on baseline-corrected measurements of RR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The effect of evobrutinib on baseline-corrected measurements of QT interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The effect of evobrutinib on baseline-corrected measurements of QTcF was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The effect of evobrutinib on baseline-corrected measurements of QTcP was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The effect of evobrutinib on baseline-corrected measurements of PR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The effect of evobrutinib on baseline-corrected measurements of QRS duration was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

Participants received single oral dose of moxifloxacin 400 mg tablet on Day 1 in fasted state in Period 1, followed by single oral dose of Evobrutinib 225 mg solution on Day 8 in fasted state in Period 2, followed by single oral dose of Placebo in fasted state on Day 15 in Period 3, and 45 mg of dose of single oral solution of evobrutinib in fasted state on Day 22 in period 4. A washout period of 7 days was maintained between 4 treatment periods

Participants received single oral dose of evobrutinib 45 mg solution on Day 1 in fasted state in Period 1, followed by single oral dose of Placebo on Day 8 in fasted state in Period 2, followed by single oral dose of 225 mg evobrutinib solution in fasted state on Day 15 in Period 3, and 400 mg of dose of single oral tablet of moxifloxacin in fasted state on Day 22 in period 4. A washout period of 7 days was maintained between 4 treatment periods

Participants received single oral dose of evobrutinib 225 mg solution on Day 1 in fasted state in Period 1, followed by single oral dose of 45 mg evobrutinib solution on Day 8 in fasted state in Period 2, followed by single oral dose of 400 mg moxifloxacin tablet in fasted state on Day 15 in Period 3, and single oral dose of Placebo in fasted state on Day 22 in period 4. A washout period of 7 days was maintained between 4 treatment periods

Total of all reporting groups

Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition

A linear mixed-effects model was used to analyze the relationship between moxifloxacin concentrations and ΔQTc. Based on this model, drug-induced ΔΔQTc and its two-sided 90% CI was predicted. The higher geometric mean Cmax calculated based on the PK and ECG Analysis Sets was considered.

All participants who had a baseline Holter ECG in triplicate and at least one post baseline Holter ECG in triplicate with a time-matched concentration.

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment.Therefore, an AE can be any unfavorable and unintended sign (including an abnormallaboratory finding), symptom, or disease temporally associated with the use of amedicinal product, regardless if it is considered related to the medicinal product.Serious AE: AE that resulted in any of the following outcomes: death; life threatening;persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization;congenital anomaly/birth defect. TEAEs are defined as AEs that were reported orworsened on or after start of study drug dosing through the Safety Follow-up Visit.TEAEs included both serious TEAEs and non-serious TEAEs. Treatment related AEs:reasonably related to the study drug/study treatment.

The safety analysis set included all participants who were administered any dose of any study intervention.

Severity of adverse events (AE) were assessed by the investigator. The Investigator assessed the intensity of each AE and SAE reported during the study and assigned it to 1 of the following categories:

1. Mild: A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. 2. Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 3. Severe: A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Number of participants with severe adverse events were reported.

The safety analysis set included all participants who were administered any dose of any study intervention.

The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities from baseline were reported. Clinically Significance was decided by investigator.

The safety analysis set included all participants who were administered any dose of any study intervention.

Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.

The safety analysis set included all participants who were administered any dose of any study intervention.

The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities were reported. Clinically significance was decided by investigator.

The safety analysis set included all participants who were administered any dose of any study intervention.

AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.

The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.

The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.

Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.

The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.

Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.

AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.

Cmax is the maximum observed plasma concentration. Cmax was obtained directly from the concentration versus time curve.

The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.

The AUC from time zero (= dosing time) extrapolated to infinity, based on the predicted value for the concentration at t last, as estimated using the linear regression from lambda (λ)z determination.

The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.

Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

The PK Analysis Set was a subset of the SAF, and the PK population included all participants: who had completed the study without any relevant protocol deviations and factors likely to affect the comparability of PK results and with adequate study intervention compliance and with evaluable PK data, i.e. no missing values for primary endpoints.

The effect of evobrutinib on baseline-corrected measurements of Heart rate was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The safety analysis set included all participants who were administered any dose of any study intervention.

The effect of evobrutinib on baseline-corrected measurements of RR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The safety analysis set included all participants who were administered any dose of any study intervention.

The effect of evobrutinib on baseline-corrected measurements of QT interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The safety analysis set included all participants who were administered any dose of any study intervention.

The effect of evobrutinib on baseline-corrected measurements of QTcF was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The safety analysis set included all participants who were administered any dose of any study intervention.

The effect of evobrutinib on baseline-corrected measurements of QTcP was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The safety analysis set included all participants who were administered any dose of any study intervention.

The effect of evobrutinib on baseline-corrected measurements of PR interval was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The safety analysis set included all participants who were administered any dose of any study intervention.

The effect of evobrutinib on baseline-corrected measurements of QRS duration was summarized by treatment and time points using descriptive statistics. Absolute change from baseline values was reported.

The safety analysis set included all participants who were administered any dose of any study intervention.

Participants received single oral dose of Moxifloxacin 400mg in treatment period 1, 2, 3 or 4under fasted condition

Participants received single oral dose of Evobrutinib 45 milligram (mg) in treatment period 1, 2, 3 or 4 under fasted condition

Participants received single oral dose of Evobrutinib 225 mg in treatment period 1, 2, 3 or 4 under fasted condition